ATE552013T1 - Zubereitungen zur oralen anwendung - Google Patents

Zubereitungen zur oralen anwendung

Info

Publication number
ATE552013T1
ATE552013T1 AT01963455T AT01963455T ATE552013T1 AT E552013 T1 ATE552013 T1 AT E552013T1 AT 01963455 T AT01963455 T AT 01963455T AT 01963455 T AT01963455 T AT 01963455T AT E552013 T1 ATE552013 T1 AT E552013T1
Authority
AT
Austria
Prior art keywords
preparation
preparations
oral use
substance
medicinal substance
Prior art date
Application number
AT01963455T
Other languages
English (en)
Inventor
Hideki Murakami
Shoji Takebe
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26599342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE552013(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE552013T1 publication Critical patent/ATE552013T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01963455T 2000-09-06 2001-09-06 Zubereitungen zur oralen anwendung ATE552013T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000270061 2000-09-06
JP2001231682 2001-07-31
PCT/JP2001/007718 WO2002020058A1 (en) 2000-09-06 2001-09-06 Preparations for oral administration

Publications (1)

Publication Number Publication Date
ATE552013T1 true ATE552013T1 (de) 2012-04-15

Family

ID=26599342

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01963455T ATE552013T1 (de) 2000-09-06 2001-09-06 Zubereitungen zur oralen anwendung

Country Status (13)

Country Link
US (1) US7501409B2 (de)
EP (1) EP1316316B1 (de)
JP (1) JP4588973B2 (de)
KR (1) KR100610131B1 (de)
CN (1) CN1264574C (de)
AT (1) ATE552013T1 (de)
AU (2) AU8444401A (de)
CA (1) CA2420461C (de)
ES (1) ES2381862T3 (de)
HK (1) HK1052879A1 (de)
MX (1) MXPA03001958A (de)
NZ (1) NZ524572A (de)
WO (1) WO2002020058A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219516D0 (en) * 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil
JP5054921B2 (ja) * 2004-02-05 2012-10-24 太陽化学株式会社 多孔質シリカを含有する吸着能付与剤
CN101771613B (zh) * 2004-06-30 2012-11-07 松下电器产业株式会社 通信装置以及通信方法
US8645578B2 (en) * 2004-12-22 2014-02-04 Intel Corporaton Routing of messages
CA2700224A1 (en) * 2007-09-19 2009-03-26 Asahi Breweries, Ltd. Method of producing granules containing natural products derived substance such as chinese orthodox medicine extracts, crude drug extracts, and extracts derived from natural substances, and producing a tablet in use of said granules
WO2011039527A1 (en) 2009-09-30 2011-04-07 Merck Sharp & Dohme Ltd Formulations for c-met kinase inhibitors
CA2844604C (en) * 2011-08-10 2017-07-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ethanediamide derivatives
DK2817000T3 (da) * 2012-02-21 2021-10-11 Towa Pharmaceutical Europe S L Orale farmaceutiske sammensætninger af dabigatranetexilat
JP6037489B2 (ja) * 2012-08-14 2016-12-07 シュエンジュウ・ファーマ・カンパニー・リミテッド 二環性基置換ピリミジン化合物
CN105899510A (zh) * 2013-08-08 2016-08-24 拜耳制药股份公司 取代的咪唑并[1,2-a]吡嗪羧酰胺及其用途
EP3082428A4 (de) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5-inhibitorpulverformulierungen und zugehörige verfahren
EP3034070A1 (de) * 2014-12-18 2016-06-22 Omya International AG Verfahren zur Herstellung eines pharmazeutischen Abgabesystems
EP3069713A1 (de) 2015-03-20 2016-09-21 Omya International AG Dispergierbare dosierungsform
WO2017112672A1 (en) 2015-12-23 2017-06-29 Colgate-Palmolive Company Storage-stable solid peroxymonosulfate composition
CN114869786B (zh) 2016-08-11 2025-08-05 高露洁-棕榄公司 针对顽渍的过一硫酸盐牙粉组合物
US10912778B2 (en) 2016-12-14 2021-02-09 Respira Therapeutics, Inc. Methods for treatment of pulmonary hypertension
SE542968C2 (en) 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
CN109438421A (zh) * 2018-11-13 2019-03-08 扬州市三药制药有限公司 一种阿伐那非中间体的精制纯化方法
EP4200025A1 (de) 2021-01-25 2023-06-28 Colgate-Palmolive Company Feste mundpflegezusammensetzungen mit pvp und hec als bindemittelsystem
AU2022224633B2 (en) 2021-02-19 2024-10-24 Colgate-Palmolive Company Peroxymonosulfate whitening strips
WO2022226369A1 (en) 2021-04-23 2022-10-27 Colgate-Palmolive Company Solid oral care compositions

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19501480A1 (de) 1995-01-19 1996-07-25 Bayer Ag 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
DE19501482A1 (de) 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one
DE19501481A1 (de) 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
US6069156A (en) 1995-04-10 2000-05-30 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as cGMP-PDE inhibitors
AU698028B2 (en) 1995-05-18 1998-10-22 Altana Pharma Ag Phenyldihydrobenzofurans
US6080782A (en) 1995-05-18 2000-06-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Cyclohexyl dihydrobenzofuranes
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
DE19541264A1 (de) 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
HU221380B1 (en) 1996-01-31 2002-09-28 Byk Gulden Lomberg Chem Fab Phosphodiesterase inhibitor phenanthridines derivatives and use thereof
US6127378A (en) 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
DE69720542D1 (de) 1996-05-31 2003-05-08 Mochida Pharm Co Ltd PYRIDOCARBAZOL DERIVATE DIE EINEN cGMP-PDE INHIBILIERENDEN EFFEKT HABEN
CA2277017C (en) 1997-01-06 2002-11-26 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
JPH10240446A (ja) 1997-02-27 1998-09-11 Nec Ic Microcomput Syst Ltd 編集図形選択システム
AU6230098A (en) 1997-02-27 1998-09-18 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
JPH10298062A (ja) 1997-04-24 1998-11-10 Pfizer Pharmaceut Co Ltd 口腔内速溶型錠剤
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
GT199900061A (es) 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
JP2000095759A (ja) 1998-07-21 2000-04-04 Takeda Chem Ind Ltd 三環性化合物、その製造法および剤
JP2000072751A (ja) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd イソキノリノン誘導体
JP2000072675A (ja) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd 医薬組成物
JP2000178204A (ja) * 1998-10-05 2000-06-27 Eisai Co Ltd ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
WO2000020033A1 (en) 1998-10-05 2000-04-13 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
JP2000119198A (ja) * 1998-10-16 2000-04-25 Eisai Co Ltd 苦味等の隠蔽されたホスフォジエステラーゼ阻害剤含有経口製剤
JP2000191518A (ja) * 1998-10-19 2000-07-11 Eisai Co Ltd 溶解性の改善された口腔内速崩壊性錠剤
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
EP1136072A4 (de) 1998-12-02 2004-12-15 Mochida Pharm Co Ltd Zubereitung zur verabreichung in den harnleiter
WO2000039099A1 (en) 1998-12-24 2000-07-06 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
CN102584799A (zh) * 1999-09-16 2012-07-18 田边三菱制药株式会社 含氮的6-员芳香环化合物
AU7683500A (en) 1999-10-12 2001-04-23 Takeda Chemical Industries Ltd. Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof

Also Published As

Publication number Publication date
US20030195220A1 (en) 2003-10-16
CN1462193A (zh) 2003-12-17
EP1316316B1 (de) 2012-04-04
CA2420461A1 (en) 2003-02-26
ES2381862T3 (es) 2012-06-01
WO2002020058A1 (en) 2002-03-14
EP1316316A1 (de) 2003-06-04
HK1052879A1 (en) 2003-10-03
MXPA03001958A (es) 2003-06-24
AU2001284444B2 (en) 2006-05-25
JP4588973B2 (ja) 2010-12-01
AU8444401A (en) 2002-03-22
KR100610131B1 (ko) 2006-08-09
CA2420461C (en) 2008-08-12
CN1264574C (zh) 2006-07-19
KR20030029921A (ko) 2003-04-16
US7501409B2 (en) 2009-03-10
EP1316316A4 (de) 2009-09-09
NZ524572A (en) 2004-08-27

Similar Documents

Publication Publication Date Title
ATE552013T1 (de) Zubereitungen zur oralen anwendung
HUP0204159A3 (en) Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction
IL163653A (en) Wafer-shaped pharmaceutical preparation for administering active substances having an unpleasant or bitter taste via the oral mucosa and use of at least one carbon dioxide-forming substance for masking the unpleasant taste of said preparation
PL334656A1 (en) Dosage forms and methods of achieving betterement in cases of erection disorderamong male patients
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
AR028426A1 (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero
ATE429213T1 (de) Mucoadhäsive zerfallsfähige arzneizubereitung zur wirkstoffverabreichung in der veterinär- und humanmedicin
AR033168A1 (es) Solucion oral de aripiprazol
DE60117615D1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
HUP0401816A3 (en) Prostaglandin compositions and their use for preparation of medicaments sutable for treatment of male erectile dysfunction
EA200501690A1 (ru) Композиция, включающая ингибитор pde4 и ингибитор pde5
NO20042208L (no) Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter
HUP0400548A3 (en) Use of combinations of iop-reducing active inoredient for preparation of pharmaceutical compositions available for treatment glaucoma
HUP0301460A3 (en) Use of antiprogestins for producing pharmaceutical compositions for prohylaxis and treatment of hormone-dependent diseases
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
PT1441769E (pt) Formulacoes farmaceuticas contendo baixa concentracao de peroxido para tratamento ou prevencao de infeccoes vaginais
ATE308328T1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
DE60138733D1 (de) Arzneimittel zur behandlung und vermeidung neurogener schmerzen
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
WO2002092565A3 (en) 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists
HUP0302535A3 (en) Peptide compounds, pharmaceutical compositions containing them and their use for treatment of no-mediated diseases
HUP0203181A3 (en) Peptides for treatment of erectile dysfunction, pharmaceutical compositions and their use
DE602004013763D1 (de) Amoxycillin und clavulanat enthaltende pharmazeutische brausefromulierung
EP1337265A4 (de) Behandlungsmethode mit der substanz p